As the U.S. stock market experiences a pullback with major indexes like the Nasdaq and S&P 500 declining ahead of crucial inflation data, investors are closely monitoring economic indicators such as GDP growth and jobless claims that impact small-cap companies. In this context, identifying high-growth tech stocks requires a focus on innovation potential and resilience amidst fluctuating market conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ACADIA Pharmaceuticals | 10.59% | 25.17% | ★★★★★☆ |
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.11% | 31.65% | ★★★★★★ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Workday | 11.29% | 31.64% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.88% | 74.81% | ★★★★★☆ |
| Zscaler | 15.74% | 40.36% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
ADMA Biologics (ADMA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $3.81 billion.
Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, contributing $465.17 million, and its Plasma Collection Centers, adding $8.86 million. The company's focus on plasma-derived biologics supports its operations in addressing immune deficiencies and infectious diseases across various markets.
ADMA Biologics showcases robust growth with a 20.6% annual revenue increase and an impressive 23.3% forecast in earnings growth per year, outpacing the broader U.S. market significantly. Recent financial maneuvers, including a $300 million credit agreement and strategic share repurchases totaling $14.98 million, underline its aggressive capital management strategy aimed at fueling further expansion. With earnings having surged by over 500% in the past year alone, ADMA stands out for its dynamic approach to scaling operations and enhancing shareholder value amidst a competitive biotech landscape.
- Click to explore a detailed breakdown of our findings in ADMA Biologics' health report.
Explore historical data to track ADMA Biologics' performance over time in our Past section.
Viant Technology (DSP)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Viant Technology Inc. is an advertising technology company with a market cap of $569.08 million.
Operations: The company generates revenue primarily through its enterprise software platform, which brought in $318.47 million. The focus is on providing advertising technology solutions, leveraging its platform to drive business growth.
Viant Technology's recent strategic moves, including a partnership with AdTegral and integration with Wurl for scene-level contextual intelligence in CTV advertising, underscore its innovative approach within the digital advertising space. These initiatives not only enhance Viant's DSP capabilities but also expand access to premium inventory and advanced targeting options, aligning well with industry shifts towards more precise and effective ad placements. Financially, Viant reported a significant increase in sales from $65.87 million to $77.85 million year-over-year for Q2 2025, alongside modest net income growth to $0.29 million from $0.055 million, reflecting improved operational efficiency and market positioning expected to drive future revenue growth forecasted between $83.5 million and $86.5 million for Q3 2025.
- Delve into the full analysis health report here for a deeper understanding of Viant Technology.
Assess Viant Technology's past performance with our detailed historical performance reports.
Roku (ROKU)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market cap of $14.59 billion.
Operations: The company generates revenue primarily through its Platform segment, which accounts for $3.80 billion, and its Devices segment, contributing $595.16 million. The Platform segment significantly outweighs the Devices in terms of revenue contribution.
Amidst a challenging landscape, Roku has demonstrated resilience and innovation, notably with the launch of its first-ever Roku TV smart projector and the introduction of Howdy, a low-cost SVOD service. These initiatives reflect Roku's commitment to expanding its ecosystem and enhancing user engagement through hardware integration and content accessibility. Financially, the company marked a significant turnaround with Q2 revenue jumping to $1.11 billion from $968 million year-over-year, alongside a shift to net profitability at $10.5 million compared to last year's loss of $33.95 million. Additionally, an authorized share repurchase program up to $400 million underscores confidence in long-term value creation despite current unprofitability challenges.
- Click here to discover the nuances of Roku with our detailed analytical health report.
Gain insights into Roku's past trends and performance with our Past report.
Seize The Opportunity
- Dive into all 66 of the US High Growth Tech and AI Stocks we have identified here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Viant Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com